WO2004019966A1 - タンパク質溶液製剤の安定化方法 - Google Patents
タンパク質溶液製剤の安定化方法 Download PDFInfo
- Publication number
- WO2004019966A1 WO2004019966A1 PCT/JP2003/010754 JP0310754W WO2004019966A1 WO 2004019966 A1 WO2004019966 A1 WO 2004019966A1 JP 0310754 W JP0310754 W JP 0310754W WO 2004019966 A1 WO2004019966 A1 WO 2004019966A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- solution
- magnetic field
- preparation
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
Definitions
- the present invention relates to a method for stabilizing a protein solution preparation and a container for storing the protein solution preparation. More specifically, the present invention relates to a method for stabilizing a physiologically active protein preparation by storing the protein solution preparation under magnetic field lines, and a storage container for the protein solution preparation provided with a magnetic field generator. The method and the container of the present invention suppress the association of bioactive proteins and are particularly useful for stabilizing protein solution preparations. Background art
- bioactive protein preparations have been provided in a stable supply. Many of these bioactive proteins are known to associate in aqueous solutions, which is a major factor in reducing the stability of formulations. Therefore, in order to ensure the stability of these preparations, they are provided as freeze-dried preparations or in the form of protein solution preparations to which various additives for improving the stability are added.
- a stabilizing effect has been found by adding polymers such as human serum albumin or purified gelatin as a stabilizer, or high molecules such as polyols, and low molecules such as amino acids and surfactants.
- polymers such as human serum albumin or purified gelatin as a stabilizer, or high molecules such as polyols, and low molecules such as amino acids and surfactants.
- adding a biologically-derived polymer such as a protein as a stabilizing agent requires a very complicated process to remove contaminants such as viruses derived from the stabilizing agent. There was a problem.
- heat stress may cause further problems such as aggregation and aggregation.
- An object of the present invention is to provide a method for suppressing the formation of an aggregate in a solution state of a protein having a physiological activity such as an antibody, an enzyme, a hormone, or a cytokin, and improving the stability of a protein solution preparation. is there. Disclosure of the invention
- the present invention provides the following:
- a method for stabilizing a protein solution preparation comprising storing the protein solution preparation under magnetic field lines.
- physiologically active protein is selected from an antibody, an enzyme, a cytokin, and a hormone.
- hematopoietic factor is erythropoietin or granulocyte colony stimulating factor.
- a storage container for a protein solution preparation equipped with a magnetic field generator (9) A storage container for a protein solution preparation equipped with a magnetic field generator.
- a method for stabilizing a protein-containing solution comprising storing the protein-containing solution under magnetic field lines.
- a stabilized protein preparation prepared from a protein bulk production solution stored under magnetic field lines.
- a protein solution preparation comprising storing a protein solution preparation under magnetic field lines A method for suppressing the formation of aggregates of an agent.
- FIG. 1 is a schematic diagram showing an acceleration test of an EPO injection preparation under magnetic field lines.
- FIG. 2 shows one embodiment of storing a solution preparation by the method of the present invention. a is a side view and b is a top view.
- FIG. 3 is a side view of one embodiment of storing a solution preparation by the method of the present invention.
- FIG. 4 shows one embodiment in which the G—C S F solution is stored under magnetic field lines.
- the protein in the present invention is preferably, but not limited to, a bioactive protein.
- the protein solution of the present invention provides a method for stabilizing not only pharmaceuticals but also all protein-containing solutions that require stabilization of proteins contained in foods, cosmetics and the like.
- Bioactive proteins include, but are not limited to, antibodies, enzymes, cytokins, and hormones.
- hematopoietic factors such as granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), erythropoietin (EP II), tropopoetin, interferon, IL-11 and IL-1 6 cytochromes, immunoglobulins such as monoclonal and humanized antibodies, tissue plasminogen activator (TPA), perokinase, serum albumin, blood coagulation factor VIII, lebutin, insulin, stem cell growth factor ( SCF), but is not limited to these.
- G-CSF granulocyte colony stimulating factor
- GM-CSF granulocyte macrophage colony stimulating factor
- EP II erythropoietin
- TPA tissue plasminogen activator
- perokinase serum albumin
- blood coagulation factor VIII blood coagulation factor VIII
- lebutin insulin
- SCF stem cell growth factor
- the physiologically active proteins hematopoietic factors such as EP ⁇ , G-CSF, GM-CSF, and thrompopoetin are preferable, and EP ⁇ and G-CSF are more preferable.
- immunoglobulin is preferable as the physiologically active protein, and a monoclonal antibody and a humanized antibody are more preferable.
- the bioactive protein used in the stabilizing method of the present invention is a protein having substantially the same biological activity as that of a mammal, particularly a human bioactive protein, and is obtained from a naturally-occurring protein or a recombinant gene. Preferred are those obtained by the gene recombination method.
- Bioactive protein by genetic recombination The quality is produced by bacteria such as Escherichia coli; yeast; cultured cells derived from animals such as Chinese hams evening ovary (CH ⁇ ) cells, C127 cells, COS cells, etc., extracted and separated and purified by various methods. Used. Proteins obtained by the genetic recombination method include those having the same amino acid sequence as the natural protein, or those having one or more of the amino acid sequences deleted, substituted, or added and having the biological activity described above. Including. Furthermore, proteins include those chemically modified with PEG and the like.
- physiologically active protein examples include a protein having a sugar chain.
- the origin of the sugar chain is not particularly limited, but a sugar chain added to mammalian cells is preferred.
- Mammalian cells include, for example, Chinese hamster ovary cells (CHO cells), BHK cells, COS cells, human-derived cells, etc. Among them, CH2 cells are most preferred.
- any G-CSF can be used as long as it is highly purified G-CSF.
- the G-CSF in the present invention may be produced by any method, such as those obtained by culturing a cell line of human tumor cells and extracting and separating and purifying it from various cells, or E. coli by genetic engineering techniques. Yeast bacteria; Chinese hamster ovary (CH ⁇ ) cells; cultured cells derived from animals such as C127 cells, COS cells, etc .; and extracted and separated and purified by various methods.
- it is produced using Escherichia coli, yeast or CHO cells using a genetic recombination method.
- it is produced by a CHO cell using a genetic recombination method.
- G-CSF chemically modified with PEG or the like is included (see International Patent Application Publication No. WO 90/12874).
- EPO When the physiologically active protein is EPO, EPO may be produced by any method, extracted from human urine by various methods, separated and purified, genetic engineering techniques (for example, -No. 12288), which are produced in Chinese hamster ovary cells (CH B), BHK cells, COS cells, human-derived cells, etc., and extracted and separated and purified by various methods. Furthermore, it includes EPO chemically modified with PEG etc. (International Patent Application Publication No. 8 7 4). In addition, EPO without sugar chain is also chemically modified with PEG or the like.
- EPO analogs that have been modified to increase the number of one or more glycosylation sites at the N-linked carbohydrate chain binding site or the O-linked carbohydrate chain binding site in the amino acid sequence of EPO (e.g., Japanese Patent Application Laid-Open No. Hei 08-151, 398, and Japanese Patent Application Laid-Open No. Hei 8-520603).
- the amount of sugar chains may be increased by increasing the content of sialic acid or the like without changing the number of sugar chain binding sites.
- the monoclonal antibody may be produced by any method.
- a monoclonal antibody is basically immunized with a sensitizing antigen according to a usual immunization method using a known technique, and the obtained immunocytes are fused with a known parent cell by a usual cell fusion method to give a normal screen. It can be prepared by screening monoclonal antibody-producing cells by the screening method.
- a recombinant antibody produced by cloning an antibody gene from a hybridoma, integrating it into an appropriate vector, introducing this into a host, and using a gene recombination technique can be used (for example, Carl, AK Borrebaeck, James, W. Larrick, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990).
- cDNA for the variable region (V region) of the antibody is synthesized from the hybridoma mRNA using reverse transcriptase.
- DNA encoding the V region of the desired antibody is obtained, it is ligated to the DNA encoding the desired antibody constant region (C region) and inserted into an expression vector.
- DNA encoding the V region of the antibody may be incorporated into an expression vector containing the DNA of the C region of the antibody.
- An expression control region for example, an enhancer, is incorporated into an expression vector so that expression is performed under the control of a promoter.
- host cells can be transformed with this expression vector to express the antibody.
- a recombinant antibody artificially modified for the purpose of, for example, reducing the antigenicity to humans such as a chimeric antibody and a humanized antibody
- modified antibodies use known methods Can be manufactured.
- a chimeric antibody is an antibody composed of a heavy chain and light chain variable region of a mouse antibody and a heavy chain and light chain constant region of a human antibody, and encodes a mouse antibody variable region. It can be obtained by ligating DNA to DNA encoding the constant region of a human antibody, inserting this into an expression vector, and introducing into a host to produce.
- the humanized antibody is also called a reshaped human antibody, and the complementarity determining region (CDR) of a non-human mammal, such as a mouse antibody, is transferred to the complementarity determining region of a human antibody.
- CDR complementarity determining region
- This method is also known for its general gene recombination technique. Specifically, a DNA sequence designed to link the CDR of a mouse antibody and the framework region (FR) of a human antibody was prepared by constructing a DNA sequence having an overlapping portion at the end. It is synthesized by PCR from individual oligonucleotides. The obtained DNA is ligated to DNA encoding the constant region of a human antibody, then incorporated into an expression vector, and introduced into a host to produce it (European Patent Application Publication No.
- a preferred example of such a reshaped humanized antibody is a humanized anti-IL-6 receptor antibody (hPM-1) (see International Patent Application Publication No. WO 92-19759).
- hPM-1 humanized anti-IL-6 receptor antibody
- a humanized anti-HM1.24 antigen monoclonal antibody see International Patent Application Publication No. WO98-145580
- anti-PTH r P antibody see International Patent Application Publication No. W ⁇ 98-138338
- humanized anti-tissue factor antibody see International Patent Application Publication No. WO99-51734
- a method for obtaining a human antibody is known.
- a human lymphocyte is sensitized in vitro with a desired antigen or a cell expressing the desired antigen, and the sensitized lymphocyte is fused with a human myeloma cell such as U266 to obtain a desired human having an antigen-binding activity.
- Antibodies can also be obtained (see Japanese Patent Publication No. 1-59878).
- a desired human antibody can be obtained by immunizing a transgenic animal having the entire repertoire of human antibody genes with an antigen (International Patent Application Publication Nos.
- a technique for obtaining a human antibody by panning using a human antibody library is also known.
- a phage that binds to an antigen can be selected by expressing the variable region of a human antibody as a single-chain isomer (scFv) on the surface of a phage by the phage display method.
- scFv single-chain isomer
- a suitable expression vector can be prepared based on the sequence to obtain a human antibody.
- These methods are already well known and can be referred to WO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, WO 95/15388. .
- antibodies produced by transgenic animals or the like are also preferred.
- antibodies include antibody fragments such as Fab, (Fab ') 2 , Fc, Fc', and Fd, and reconstituted antibodies such as monovalent or bivalent or more single-chain antibodies (scFV).
- the biologically active protein-containing sample may be any protein-containing sample, regardless of whether it is a biologically-derived protein or a recombinant protein.
- This refers to a culture medium for mammalian cells such as CHO cells containing active proteins, or a medium that has been subjected to a certain treatment such as partial purification.
- the bioactive protein solution formulation may further contain, if desired, a surfactant, a stabilizer such as an amino acid, a diluent, a solubilizing agent, an excipient, a pH adjuster, a soothing agent, a buffer, in addition to the bioactive protein Agents, sulfur-containing reducing agents, antioxidants and the like. It is produced by dissolving these components in a commonly used buffer solution.
- a surfactant such as an amino acid, a diluent, a solubilizing agent, an excipient, a pH adjuster, a soothing agent, a buffer, in addition to the bioactive protein Agents, sulfur-containing reducing agents, antioxidants and the like. It is produced by dissolving these components in a commonly used buffer solution.
- Bioactive protein solution formulations are usually supplied in sealed, sterile plastic or glass vials, ampules, containers of defined volume such as syringes, and large volume containers such as bottles.
- the stabilization method of the present invention can be used for solution preparations in any of these container shapes. Preferred is a prefilled syringe It is a solution preparation of.
- pial is also preferably exemplified.
- a solution preparation of a physiologically active protein is stored under magnetic field lines.
- the magnetic field generator include, but are not limited to, a magnet, a magnetic head manufactured by a semiconductor process, and an arrangement of minute coils to flow electricity. It is preferable to store the magnet by placing it around the solution preparation container because it is inexpensive and simple.
- One embodiment of the present invention is shown in FIG.
- the form and arrangement direction of the magnet are not particularly limited, but a sheet-like magnet is preferable in consideration of the packaging form.
- a syringe may be arranged on one sheet magnet, or a syringe may be arranged between two sheet magnets as shown in FIG.
- a vial may be arranged on a sheet-like magnet.
- the arrangement of the bioactive protein solution preparation and the magnet may be any arrangement as long as the solution preparation is stored under the magnetic field lines.
- the direction of magnetization of the magnet may be any direction as long as the solution preparation is stored under the magnetic field lines.
- the upper surface of the magnet can be an N pole
- the lower surface can be an S pole
- the upper surface can be an S pole and the lower surface can be an N pole.
- the surface in contact with the syringe or vial may be the north pole or the south pole.
- one of the two faces that contact the syringe can be the north pole, the other can be the south pole, or both can be the same pole.
- the magnetic flux density is 1 mT or more, preferably 1 to 450 mT, and more preferably 1 to 150 mT.
- the present invention further provides a container for storing a bioactive protein solution preparation, which is provided with a magnetic field generator.
- a storage container is provided with the above-described device for generating magnetic field lines and a storage portion for the solution preparation.
- the storage container may be a storage box, a refrigerator, a container, or the like.
- the present invention further provides a method for stabilizing a bulk protein solution which comprises storing the bulk protein solution under magnetic field lines.
- a stabilized protein preparation can be prepared from a protein bulk solution stored under magnetic field lines.
- the stabilized protein preparation may be a solution preparation or a lyophilized preparation.
- physiologically active protein solution solution stored by the method of the present invention suppressed the formation of aggregates even after long-term storage.
- purity test of erythropoietin (EPO) injection 750IU
- non-magnetic field 40 ° C for 2 weeks and 1 month
- the present inventors are not bound by a particular theory, but consider the mechanism of action of the present invention as follows. That is, in general, the association of proteins occurs when the hydrophobic site of the protein molecule appears on the surface of the three-dimensional structure of the protein molecule due to some effect such as heat or collision with the container surface, and the hydrophobic sites are bonded to each other. It is thought to be caused by fitting. Therefore, if the protein in the aqueous solution can be restrained by some force, it is thought that random collision of protein molecules can be suppressed.
- the method and the storage container of the present invention are based on a technical idea completely different from the idea of adding a conventional stabilizer to stabilize a bioactive protein preparation, and can be obtained by a simple method. Long-term storage is possible by suppressing the formation of coalescence. By using the method and the storage container of the present invention, the amount of additives used can be reduced.
- a magnet (approximately 100 mT) was attached to the EPO injection preparation (750 IU) (see Fig. 1) and stored in a 40 ° C constant-temperature bath for 2 weeks and 1 month before evaluation.
- the upper surface of the sheet-shaped magnet is an N-pole, and the lower surface is an S-pole.
- Each sample described above is used as a sample solution. Take exactly 60 PL of the sample solution, add exactly 20 pL of the non-reducing sample buffer * 1 , and heat in a 50 ° C water bath for 15 minutes. After heating, add exactly 4.0 pL of the BPB solution * 2 to make a sample for electrophoresis.
- Electrophoresis device Electrophoresis device manufactured by TEFCO
- Electrophoresis gel Slab gel [Gradient 8% -16%, 15Well, 1.5mm thickness, TEFCO Electrophoresis current: 25mA / sheet constant current
- Electrophoresis Buffer electrophoresis buffer * 4 3-1-2) Western blot
- Transfer condition current 65 ⁇ 2mA, transfer time 120 minutes
- Non-reducing sample buffer Dissolve 74.48 mg of ethylenediaminetetraacetate sodium and 5.0 g of sodium lauryl sulfate in 50 mL of Tris'HCl solution.
- BPB solution Mix 0.625 mL of Tris-HCl solution, 3.5 mL of concentrated glycerin and 5 mg of bromophenol blue solution. Store refrigerated at 4 ° C.
- Buffer for electrophoresis 3.0 g of trishydroxymethylaminoaminomethane and 14.4 g of dalysine are added to 600 mL of water, and sodium lauryl sulfate l.Og is added thereto to dissolve, and then water is added to make 100 mL. .
- Problot membrane polyvinylidene difluoride membrane filter (8cm x 8cm, manufactured by Applied Biosystems) or equivalent.
- Tris-HCl solution Tris hydrid xymethylaminomethane 3.0 in 30 mL of water After adjusting the pH to 6.8 by adding lmol / L hydrochloric acid TS, make up to 100 mL with water and store at 4 ° C in a refrigerator.
- UV absorption photometer (measurement wavelength: 214mn)
- Mobile phase Perform a mixed gradient of two solutions using the following two solutions.
- Solution A Water, acetonitrile, trifluoroacetic acid mixture (400: 100: 1)
- Solution B Mixed solution of acetonitrile, water and trifluoroacetic acid (400: 100: 1)
- Gradient operation After equilibrating the column with a solution B concentration of 35%, inject the sample solution and standard solution. After maintaining the B solution concentration at 35% for 5 minutes, perform a linear gradient so that the B solution concentration becomes 100% in 15 minutes. Then hold it for 2 minutes.
- Tables 1 and 2 show the results of liquid chromatogram evaluation of the formulation for injection of EP II (750 IU) accelerated under magnetic field lines at 40 ° C for 2 weeks and 1 month.
- G-CSF solution (G-CSF concentration: about 0.5 mg / mL) was filtered with a disposable filter, and a 5-mL glass vial filled with lmL was used as a test sample.
- test samples were stored in a thermostat at 30 ° C in the presence of magnetic field lines (about 100 mT * 8 ) and under the non-magnetic field lines * 9 (see Fig. 4).
- magnetic field lines about 100 mT * 8
- non-magnetic field lines * 9 see Fig. 4
- the surface of the sheet magnet in contact with the vial was the N pole, and the opposite surface was the S pole.
- Table 3 shows the G—CSF aggregate content after storage at 30 ° C. for 2 weeks. Table 3 Shadows of magnetic field lines on G-CSF aggregate formation behavior
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004532706A JP4489591B2 (ja) | 2002-08-27 | 2003-08-26 | タンパク質溶液製剤の安定化方法 |
US10/524,019 US20060058511A1 (en) | 2002-08-27 | 2003-08-26 | Method for stabilizing protein solution preparation |
EP03791289A EP1541165A4 (en) | 2002-08-27 | 2003-08-26 | METHOD FOR STABILIZING PROTEIN PREPARATION |
AU2003257536A AU2003257536A1 (en) | 2002-08-27 | 2003-08-26 | Method of stabilizing protein solution preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-247298 | 2002-08-27 | ||
JP2002247298 | 2002-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004019966A1 true WO2004019966A1 (ja) | 2004-03-11 |
Family
ID=31972462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/010754 WO2004019966A1 (ja) | 2002-08-27 | 2003-08-26 | タンパク質溶液製剤の安定化方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060058511A1 (ja) |
EP (1) | EP1541165A4 (ja) |
JP (1) | JP4489591B2 (ja) |
AU (1) | AU2003257536A1 (ja) |
WO (1) | WO2004019966A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006132352A1 (ja) * | 2005-06-10 | 2006-12-14 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2を含有する医薬組成物 |
KR101140483B1 (ko) * | 2007-05-02 | 2012-07-11 | 에프. 호프만-라 로슈 아게 | 단백질을 안정화시키는 방법 |
US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
US8945543B2 (en) | 2005-06-10 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
US9241994B2 (en) | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005056605A1 (ja) * | 2003-12-12 | 2007-12-06 | 中外製薬株式会社 | 3量体以上の受容体を認識する改変抗体 |
TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
JPWO2005056602A1 (ja) * | 2003-12-12 | 2008-03-06 | 中外製薬株式会社 | アゴニスト活性を有する改変抗体のスクリーニング方法 |
TW200718780A (en) * | 2005-06-10 | 2007-05-16 | Chugai Pharmaceutical Co Ltd | Sc(Fv)2 site-directed mutant |
US7883265B2 (en) * | 2007-06-01 | 2011-02-08 | Applied Biosystems, Llc | Devices, systems, and methods for preparing emulsions |
Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6112288A (ja) | 1983-12-27 | 1986-01-20 | ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド | 真核細胞の形質転換のための補助dnaを含むベクタ− |
EP0178665A2 (en) * | 1984-10-18 | 1986-04-23 | Chugai Seiyaku Kabushiki Kaisha | Stable erythropoietin preparation and process for formulating the same |
EP0239400A2 (en) | 1986-03-27 | 1987-09-30 | Medical Research Council | Recombinant antibodies and methods for their production |
JPH01262988A (ja) * | 1988-04-11 | 1989-10-19 | Shoko Kagaku Kenkyusho:Kk | 水質改良構造物 |
JPH0159878B2 (ja) | 1982-05-21 | 1989-12-20 | Yunibaashitei Obu Karifuorunia | |
WO1990012874A2 (en) | 1989-04-21 | 1990-11-01 | Genetics Institute, Inc. | Cysteine added variants of polypeptides and chemical modifications thereof |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992019759A1 (en) | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1995001438A1 (en) | 1993-06-30 | 1995-01-12 | Medical Research Council | Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
JPH08151398A (ja) | 1989-10-13 | 1996-06-11 | Amgen | ヒトエリスロポエチン類似体 |
JPH08506023A (ja) | 1993-08-17 | 1996-07-02 | アムジエン・インコーポレーテツド | エリトロポエチン類似体 |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5584994A (en) * | 1994-11-25 | 1996-12-17 | Hattori; Toshimitsu | Apparatus for manufacturing magnetized water and magnetic force generator used therefor |
WO1998013388A1 (fr) | 1996-09-26 | 1998-04-02 | Chugai Seiyaku Kabushiki Kaisha | Anticorps contre les peptides lies a la parathormone humaine |
WO1998014580A1 (fr) | 1996-10-04 | 1998-04-09 | Chugai Seiyaku Kabushiki Kaisha | Anticorps anti-hm1.24 humain reconstitue |
WO1999051743A1 (fr) | 1998-04-03 | 1999-10-14 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humanise contre le facteur tissulaire humain (tf) et procede de production d'anticorps humanises |
JP2000229815A (ja) * | 1999-02-05 | 2000-08-22 | Toshimitsu Hattori | リポソームおよびその利用 |
WO2000051629A1 (fr) * | 1999-03-01 | 2000-09-08 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees a longue conservation |
WO2001017542A1 (fr) * | 1999-09-08 | 2001-03-15 | Chugai Seiyaku Kabushiki Kaisha | Preparation de solution de proteines et procede de stabilisation associe |
WO2001064241A1 (fr) * | 2000-02-29 | 2001-09-07 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees a long terme |
JP2001340062A (ja) * | 2000-06-01 | 2001-12-11 | Toyo Shinyaku:Kk | γ−アミノ酪酸を含有するイネ科植物の乾燥緑葉粉末の製造方法 |
WO2002017957A1 (fr) * | 2000-09-01 | 2002-03-07 | Chugai Seiyaku Kabushiki Kaisha | Preparations de solutions stabilisees sur une longue periode de temps |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3308809A (en) * | 1963-07-15 | 1967-03-14 | Milton J Cohen | Blood withdrawal device and dispenser |
US5261874A (en) * | 1991-09-16 | 1993-11-16 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Extra-corporeal blood access, sensing, and radiation methods and apparatuses |
WO1996030394A1 (en) * | 1995-03-31 | 1996-10-03 | Jakob Bohr | Method for protein folding |
US6110380A (en) * | 1998-05-15 | 2000-08-29 | Biocrystal Ltd. | Device and method for magnetic separation of biological molecules |
US6391619B1 (en) * | 2001-03-01 | 2002-05-21 | Ultra Biotech Limited | Methods and compositions for suppressing growth of algae |
-
2003
- 2003-08-26 EP EP03791289A patent/EP1541165A4/en not_active Withdrawn
- 2003-08-26 AU AU2003257536A patent/AU2003257536A1/en not_active Abandoned
- 2003-08-26 JP JP2004532706A patent/JP4489591B2/ja not_active Expired - Fee Related
- 2003-08-26 WO PCT/JP2003/010754 patent/WO2004019966A1/ja active Application Filing
- 2003-08-26 US US10/524,019 patent/US20060058511A1/en not_active Abandoned
Patent Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0159878B2 (ja) | 1982-05-21 | 1989-12-20 | Yunibaashitei Obu Karifuorunia | |
JPS6112288A (ja) | 1983-12-27 | 1986-01-20 | ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド | 真核細胞の形質転換のための補助dnaを含むベクタ− |
EP0178665A2 (en) * | 1984-10-18 | 1986-04-23 | Chugai Seiyaku Kabushiki Kaisha | Stable erythropoietin preparation and process for formulating the same |
EP0239400A2 (en) | 1986-03-27 | 1987-09-30 | Medical Research Council | Recombinant antibodies and methods for their production |
JPH01262988A (ja) * | 1988-04-11 | 1989-10-19 | Shoko Kagaku Kenkyusho:Kk | 水質改良構造物 |
WO1990012874A2 (en) | 1989-04-21 | 1990-11-01 | Genetics Institute, Inc. | Cysteine added variants of polypeptides and chemical modifications thereof |
JPH08151398A (ja) | 1989-10-13 | 1996-06-11 | Amgen | ヒトエリスロポエチン類似体 |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992019759A1 (en) | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1995001438A1 (en) | 1993-06-30 | 1995-01-12 | Medical Research Council | Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof |
JPH08506023A (ja) | 1993-08-17 | 1996-07-02 | アムジエン・インコーポレーテツド | エリトロポエチン類似体 |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
US5584994A (en) * | 1994-11-25 | 1996-12-17 | Hattori; Toshimitsu | Apparatus for manufacturing magnetized water and magnetic force generator used therefor |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1998013388A1 (fr) | 1996-09-26 | 1998-04-02 | Chugai Seiyaku Kabushiki Kaisha | Anticorps contre les peptides lies a la parathormone humaine |
WO1998014580A1 (fr) | 1996-10-04 | 1998-04-09 | Chugai Seiyaku Kabushiki Kaisha | Anticorps anti-hm1.24 humain reconstitue |
WO1999051743A1 (fr) | 1998-04-03 | 1999-10-14 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humanise contre le facteur tissulaire humain (tf) et procede de production d'anticorps humanises |
JP2000229815A (ja) * | 1999-02-05 | 2000-08-22 | Toshimitsu Hattori | リポソームおよびその利用 |
WO2000051629A1 (fr) * | 1999-03-01 | 2000-09-08 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees a longue conservation |
WO2001017542A1 (fr) * | 1999-09-08 | 2001-03-15 | Chugai Seiyaku Kabushiki Kaisha | Preparation de solution de proteines et procede de stabilisation associe |
WO2001064241A1 (fr) * | 2000-02-29 | 2001-09-07 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees a long terme |
JP2001340062A (ja) * | 2000-06-01 | 2001-12-11 | Toyo Shinyaku:Kk | γ−アミノ酪酸を含有するイネ科植物の乾燥緑葉粉末の製造方法 |
WO2002017957A1 (fr) * | 2000-09-01 | 2002-03-07 | Chugai Seiyaku Kabushiki Kaisha | Preparations de solutions stabilisees sur une longue periode de temps |
Non-Patent Citations (3)
Title |
---|
CARL, A. K. BORREBAECK; JAMES, W. LARRICK: "THERAPEUTIC MONOCLONAL ANTIBODIES", 1990, MACMILLAN PUBLISHERS LTD |
SATO, K. ET AL., CANCER RES., vol. 53, 1993, pages 851 - 856 |
See also references of EP1541165A4 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US11168344B2 (en) | 2005-03-31 | 2021-11-09 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
US8945543B2 (en) | 2005-06-10 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
US9241994B2 (en) | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
WO2006132352A1 (ja) * | 2005-06-10 | 2006-12-14 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2を含有する医薬組成物 |
US9777066B2 (en) | 2005-06-10 | 2017-10-03 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US10934344B2 (en) | 2006-03-31 | 2021-03-02 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
KR101140483B1 (ko) * | 2007-05-02 | 2012-07-11 | 에프. 호프만-라 로슈 아게 | 단백질을 안정화시키는 방법 |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
Also Published As
Publication number | Publication date |
---|---|
US20060058511A1 (en) | 2006-03-16 |
JPWO2004019966A1 (ja) | 2005-12-15 |
EP1541165A4 (en) | 2009-06-24 |
JP4489591B2 (ja) | 2010-06-23 |
AU2003257536A1 (en) | 2004-03-19 |
EP1541165A1 (en) | 2005-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004019966A1 (ja) | タンパク質溶液製剤の安定化方法 | |
JP4364645B2 (ja) | 抗体含有溶液製剤 | |
CN111971062B (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
ES2869895T3 (es) | Método de purificación de proteínas | |
ES2567198T3 (es) | Antagonistas de la IL-1 beta humana | |
ES2324046T5 (es) | Procedimiento para controlar la sialilación de proteínas producidas por un cultivo de células de mamíferos | |
NO20180694A1 (no) | Stabil, flytende formulering med lav turbiditet som omfatter et antistoff, arginin-HCl, histidin og polysorbat. | |
CA2517310C (en) | Stabilized protein-containing formulations comprising a poloxamer | |
CN105051064A (zh) | 抗TNF-α抗原结合蛋白 | |
CN107074931A (zh) | 经配制的受体多肽和相关方法 | |
JP2023081967A (ja) | ジスルフィド結合の還元を最小限にする抗体製造法 | |
AU2014318725A2 (en) | Liquid protein formulations containing ionic liquids | |
EA012802B1 (ru) | Гликозилированный il-7, получение и применение | |
KR20150080038A (ko) | 단백질 제형 및 이의 제조방법 | |
CN106661111A (zh) | 抗体制剂 | |
JP6889149B2 (ja) | 抗原結合タンパク質の荷電深層ろ過 | |
WO2021013385A1 (en) | Processes for obtaining a highly concentrated antibody solution | |
KR20150075083A (ko) | Gm-csf를 중화하는 화합물을 포함하는 액체 제제 | |
CN113382716A (zh) | 通过将药物物质和药物产品过程整体化的生物制剂制造的连续制造过程 | |
CN113453719A (zh) | 包含抗cd47抗体的制剂及其制备方法和用途 | |
JP4812228B2 (ja) | 抗体含有溶液の凝集物生成または白濁抑制方法 | |
BR112020009096A2 (pt) | método para reduzir o tempo de reconstituição de formulações proteicas secas por aspersão | |
WO1999018994A1 (fr) | Procede pour conserver la qualite d'une solution parenterale aqueuse de thrombomoduline pour l'entreposage ou la distribution | |
WO2003018056A1 (fr) | Preparations stabilisees contenant un anticorps | |
Gierach et al. | Protein drug production and formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003791289 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004532706 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2006058511 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10524019 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003791289 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10524019 Country of ref document: US |